The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.

The investment firm co-led a $125 million Series A round for Ambros Therapeutics, a Vivek Ramaswamy co-founded company with a ...

The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase of an escalating battle for control of the obesity drug market.

The financing follows a strategic shift for Orum, which shelved its original lead program and is now pursuing a potential ...

Two pilot programs would tie Medicare costs and rebates in the U.S. to what’s paid in comparable countries. Elsewhere, AstraZeneca reported a setback and an “off the shelf” cell therapy showed promise ...

The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...

Recognizing the urgent need for treatment options and guided by patient insights, Pfizer scientists have discovered a way to ...

Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...

Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive ...